161 related articles for article (PubMed ID: 38313213)
1. Brentuximab vedotin as a bridge to combination chemotherapy in gray zone lymphoma with severe liver impairment: a case report.
Asrani R; Cengiz TB; Petersen BE; Anagnostou T; Brody JD
Front Oncol; 2023; 13():1254256. PubMed ID: 38313213
[TBL] [Abstract][Full Text] [Related]
2. A Rare Case of Grey Zone Lymphoma Successfully Treated with Brentuximab Vedotin and R-CHP Chemotherapy.
Mallipudi RM; Alquran L; Shenoy VA; Leslie LA; Conti JA
Case Rep Oncol Med; 2019; 2019():4121234. PubMed ID: 31110830
[TBL] [Abstract][Full Text] [Related]
3. Brentuximab vedotin plus AVD followed by involved-node radiotherapy in a patient with classic Hodgkin lymphoma following gray zone lymphoma after autologous stem-cell transplantation failure.
Ueda N; Kato H; Kato S; Saito T; Tachibana H; Yanada M; Taji H; Kodaira T; Hosoda W; Yamamoto K
Hematology; 2023 Dec; 28(1):2207946. PubMed ID: 37183912
[TBL] [Abstract][Full Text] [Related]
4. Brentuximab vedotin maintenance after autologous stem cell transplantation for refractory gray zone lymphoma with long-term remission.
Terao T; Yuda J; Yamauchi N; Guo YM; Shimada K; Sugano M; Ishii G; Minami Y
Mol Clin Oncol; 2021 Jun; 14(6):125. PubMed ID: 33936598
[TBL] [Abstract][Full Text] [Related]
5. Unraveling the Mystery of Gray Zone Lymphoma in Human Immunodeficiency Virus-Seropositive Patients: Two Cases.
Ahluwalia A; Bondili L; Salamera J; Cholankeril M
J Hematol; 2020 Dec; 9(4):132-136. PubMed ID: 33224393
[TBL] [Abstract][Full Text] [Related]
6. How I manage patients with grey zone lymphoma.
Kritharis A; Pilichowska M; Evens AM
Br J Haematol; 2016 Aug; 174(3):345-50. PubMed ID: 27301470
[TBL] [Abstract][Full Text] [Related]
7. Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas.
Svoboda J; Bair SM; Landsburg DJ; Dwivedy Nasta S; Nagle SJ; Barta SK; Khan N; Filicko-O'Hara J; Gaballa S; Strelec L; Chong E; Mitnick S; Waite TS; King C; Ballard H; Youngman M; Gerson J; Plastaras JP; Maity A; Bogusz AM; Hung SS; Nakamura H; Nejati R; Steidl C; Lim M; Ruella M; Schuster SJ
Haematologica; 2021 Jun; 106(6):1705-1713. PubMed ID: 32414850
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL.
Pilichowska M; Pittaluga S; Ferry JA; Hemminger J; Chang H; Kanakry JA; Sehn LH; Feldman T; Abramson JS; Kritharis A; Hernandez-Ilizaliturri FJ; Lossos IS; Press OW; Fenske TS; Friedberg JW; Vose JM; Blum KA; Jagadeesh D; Woda B; Gupta GK; Gascoyne RD; Jaffe ES; Evens AM
Blood Adv; 2017 Dec; 1(26):2600-2609. PubMed ID: 29296913
[TBL] [Abstract][Full Text] [Related]
9. Gray zone lymphoma effectively treated with cyclophosphamide, doxorubicin, vincristine, prednisolone, and rituximab chemotherapy: A case report.
Hojo N; Nagasaki M; Mihara Y
World J Clin Cases; 2022 Jun; 10(17):5708-5716. PubMed ID: 35979119
[TBL] [Abstract][Full Text] [Related]
10. Combined use of pathological and genomic alteration analyses for the diagnosis of gray zone lymphoma.
Nishimura K; Miyazaki K; Suzuki K; Hachiya K; Tono Y; Tamaru S; Imai H; Miyoshi H; Ohshima K; Okugawa Y; Tawara I; Yamaguchi M
J Clin Exp Hematop; 2022; 62(4):253-257. PubMed ID: 36575002
[TBL] [Abstract][Full Text] [Related]
11. Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin.
Oregel KZ; Everett E; Zhang X; Nagaraj G
Expert Rev Anticancer Ther; 2016; 16(3):279-83. PubMed ID: 26809026
[TBL] [Abstract][Full Text] [Related]
12. Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort.
Evens AM; Kanakry JA; Sehn LH; Kritharis A; Feldman T; Kroll A; Gascoyne RD; Abramson JS; Petrich AM; Hernandez-Ilizaliturri FJ; Al-Mansour Z; Adeimy C; Hemminger J; Bartlett NL; Mato A; Caimi PF; Advani RH; Klein AK; Nabhan C; Smith SM; Fabregas JC; Lossos IS; Press OW; Fenske TS; Friedberg JW; Vose JM; Blum KA
Am J Hematol; 2015 Sep; 90(9):778-83. PubMed ID: 26044261
[TBL] [Abstract][Full Text] [Related]
13. [Grey zone lymphoma with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma: clinicopathologic characterization of 16 cases showing different patterns].
Wang L; Wang W; Li X; Guo Y; Zhu X
Zhonghua Bing Li Xue Za Zhi; 2014 May; 43(5):307-12. PubMed ID: 25030862
[TBL] [Abstract][Full Text] [Related]
14. Gene expression profiling of gray zone lymphoma.
Sarkozy C; Chong L; Takata K; Chavez EA; Miyata-Takata T; Duns G; Telenius A; Boyle M; Slack GW; Laurent C; Farinha P; Molina TJ; Copie-Bergman C; Damotte D; Salles GA; Mottok A; Savage KJ; Scott DW; Traverse-Glehen A; Steidl C
Blood Adv; 2020 Jun; 4(11):2523-2535. PubMed ID: 32516416
[TBL] [Abstract][Full Text] [Related]
15. Successful reversal of severe liver function impairment with Brentuximab vedotin in multiply relapsed/refractory classical Hodgkin lymphoma.
Spathas N; Belia M; Giannikos T; Arapaki M; Efstathopoulou M; Tsourouflis G; Gainaru G; Asimakopoulos J; Tsaftaridis P; K Angelopoulou M; Plata E; Konstantopoulos K; P Vassilakopoulos T
J BUON; 2019; 24(6):2483-2489. PubMed ID: 31983123
[TBL] [Abstract][Full Text] [Related]
16. Mediastinal large B cell lymphoma and surrounding gray areas: a report of the lymphoma workshop of the 20th meeting of the European Association for Haematopathology.
Gibson SE; Dojcinov S; Dotlic S; Hartmann S; Hsi ED; Klimkowska M; Melle F; Pileri SA; Ramsower CA; Rech K; Rimsza LM; Rodriguez-Pinilla SM; Tousseyn TA; de Jong D; Sabattini E
Virchows Arch; 2023 Dec; 483(6):733-749. PubMed ID: 37530791
[TBL] [Abstract][Full Text] [Related]
17. The utility of CD83, fascin and CD23 in the differential diagnosis of primary mediastinal large B-cell lymphoma versus classic Hodgkin lymphoma.
Aladily TN; Mansour A; Alsughayer A; Sughayer M; Medeiros LJ
Ann Diagn Pathol; 2019 Jun; 40():72-76. PubMed ID: 31075666
[TBL] [Abstract][Full Text] [Related]
18. Mutational landscape of gray zone lymphoma.
Sarkozy C; Hung SS; Chavez EA; Duns G; Takata K; Chong LC; Aoki T; Jiang A; Miyata-Takata T; Telenius A; Slack GW; Molina TJ; Ben-Neriah S; Farinha P; Dartigues P; Damotte D; Mottok A; Salles GA; Casasnovas RO; Savage KJ; Laurent C; Scott DW; Traverse-Glehen A; Steidl C
Blood; 2021 Apr; 137(13):1765-1776. PubMed ID: 32961552
[TBL] [Abstract][Full Text] [Related]
19. Safety and Efficacy of Brentuximab Vedotin in the Treatment of Classic Hodgkin Lymphoma.
Makita S; Maruyama D; Tobinai K
Onco Targets Ther; 2020; 13():5993-6009. PubMed ID: 32606807
[TBL] [Abstract][Full Text] [Related]
20. Grey zone lymphoma with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma: a clinicopathological study of 14 Epstein-Barr virus-positive cases.
Elsayed AA; Satou A; Eladl AE; Kato S; Nakamura S; Asano N
Histopathology; 2017 Mar; 70(4):579-594. PubMed ID: 27735994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
